Press-release for stocks for bolt biotherapeutics inc for bmy

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-29 (Crawled : 22:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130

| -2.87% | O: 1.48% H: 0.0% C: 0.0%
GNMSF | News | $289.67 3.83% 5.3K

| -22.34% | O: 0.0% H: 1.69% C: 1.42%
BOLT | $1.11 1.77% 51K

| -13.95% | O: 5.43% H: 0.74% C: -1.47%
BMY | $48.99 -0.31% 0.0% 9.1M

| -27.93% | O: 0.29% H: 0.22% C: -0.26%
GMAB | News | $28.54 -1.48% -1.51% 560K

| -22.89% | O: 0.37% H: 0.05% C: -0.4%
business year update financial results

| -17.16% | O: 0.75% H: 1.87% C: -1.48%
BMY | $48.99 -0.31% 0.0% 9.1M

| -37.62% | O: -0.09% H: 1.23% C: 0.61%
bdc-3042 preclinical meeting

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-10 (Crawled : 23:00) - biospace.com/
GNMSF | News | $289.67 3.83% 5.3K

| -17.24% | O: -0.39% H: 5.07% C: -0.05%
BOLT | $1.11 1.77% 51K

| -51.32% | O: 3.07% H: 8.51% C: 7.23%
BMY | $48.99 -0.31% 0.0% 9.1M

| -34.45% | O: 0.32% H: 0.16% C: -0.45%
GMAB | News | $28.54 -1.48% -1.51% 560K

| -17.53% | O: 2.33% H: 0.64% C: -0.72%
update results

| -73.57% | O: -4.05% H: 2.98% C: -7.2%
BMY | $48.99 -0.31% 0.0% 9.1M

| -21.31% | O: -1.17% H: 0.11% C: -0.39%
bdc-1001 opdivo treatment solid tumors ongoing trial therapeutics 100 phase 1 iot her2- her2 nivolumab

| -89.63% | O: -22.84% H: 0.0% C: 0.0%
BMY | $48.99 -0.31% 0.0% 9.1M

| -12.12% | O: 1.39% H: 0.0% C: 0.0%
therapeutics phase 1 iot

| -88.27% | O: 3.22% H: 8.6% C: 6.35%
BMY | $48.99 -0.31% 0.0% 9.1M

| -8.85% | O: 2.17% H: 0.0% C: 0.0%
trial therapeutics phase 1 iot

| -93.94% | O: 0.76% H: 0.0% C: -7.09%
BMY | $48.99 -0.31% 0.0% 9.1M

| -24.62% | O: -0.89% H: 0.82% C: 0.48%
treatment solid tumors collaboration iot her2+ her2- her2